Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities

Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with  advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news